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Numerous natural or disease-related alterations occur in different tissues of the body with
advancing age. Sarcopenia is defined as age-related decrease of muscle mass and strength
beginning in mid-adulthood and accelerating in people older than 60 years. Pathophysiology
of sarcopenia involves both neural and muscle dependent mechanisms and is enhanced
by multiple factors. Aged muscles show loss in fiber number, fiber atrophy, and gradual
increase in the number of ragged red fibers and cytochrome c oxidase-negative fibers.
Generalized loss of muscle tissue and increased amount of intramuscular fat are seen on
muscle imaging. However, the degree of these changes varies greatly between individ-
uals, and the distinction between normal age-related weakening of muscle strength and
clinically significant muscle disease is not always obvious. Because some of the genetic
myopathies can present at a very old age and be mild in severity, the correct diagnosis is
easily missed. We highlight this difficult borderline zone between sarcopenia and muscle
disease by two examples: LGMD1D and myotonic dystrophy type 2. Muscle magnetic
resonance imaging (MRI) is a useful tool to help differentiate myopathies from sarcopenia
and to reach the correct diagnosis also in the elderly.
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INTRODUCTION
One of the most serious consequence of aging is its effects on
skeletal muscle. The aging in muscle is a complex process to which
various physiological and pathological mechanisms contribute
(Cruz-Jentoft et al., 2010). Sarcopenia, featuring the normal age-
related changes in muscle, is defined as the slow but progressing
loss of skeletal muscle mass and strength occurring with advanc-
ing age (Morley et al., 2001). A term, skeletal muscle function
deficit (SMFD), has also been introduced in an attempt to better
define the muscle problems in advanced age (Correa-de-Araujo
and Hadley,2014). Although sarcopenia is part of the normal aging
process, it has a great impact on health and functionality, because
the mobility is impaired, the risk of falls and injuries is increased,
ability to perform activities of daily living is decreased, and there
is an increased risk of lost independence and death (Rolland et al.,
2008). Sarcopenia is common in adults over the age of 65 years
and its prevalence increases with age. The prevalence varies from
5 to 13% in 60- to 70-year olds and 11–50% for the population
aged 80 years or older and depends on what diagnostic methods
and definitions are used (Iannuzzi-Sucich et al., 2002; Wang and
Bai, 2012; Patel et al., 2013).
Muscle mass is strongly age dependent. After the age of 50,
approximately 1–2% of muscle mass is expected to be lost every
year and between the ages of 20 and 80 years muscle mass is
reduced up to 50% (Wang and Bai, 2012). Pathophysiology of
sarcopenia involves both neural- and muscle-dependent mecha-
nisms and is enhanced by multiple factors (Cruz-Jentoft et al.,
2010). Continuous age-related decrease in the number of motor
neurons leads to chronic denervation of muscle tissue. This is
one of the most important factors leading to the loss of mus-
cle fibers and total muscle mass, although multiple other factors
contribute, such as decreased physical activity, altered hormonal
status, especially anabolic hormones, decreased total caloric and
protein intake, inflammatory mediators, and factors leading to
altered protein synthesis (Doherty, 2003; Ryall et al., 2008). Mus-
cle atrophy might be induced also by increased susceptibility to
apoptosis caused by mitochondrial dysfunction (Edström et al.,
2007). The degree of these changes varies greatly between individ-
uals, and an accepted definition of sarcopenia for use in clinical
practice is still lacking (Cruz-Jentoft et al., 2010).
Age-related generalized loss of muscle tissue and the decrease
in muscle volume and thickness are seen in muscle imaging using
different techniques, such as, magnetic resonance imaging (MRI),
computed tomography (CT), or ultrasonography (Figures 1A,B).
Also, increased amount of intramuscular and intermuscular fat is
observed (Wattjes and Fischer, 2013).
PATHOLOGICAL CHANGES WITH AGING
Aged muscles show loss in fiber number and fiber size. Fiber
size reduction is more prominent in type 2 fibers. The decrease
in fiber number affects both fiber types but preferential loss is
seen in type 2, resulting in increase in the proportion of type
1 fibers (Lexell et al., 1988). Some neurogenic changes due to
motor neuron loss may be seen in muscle biopsies of very aged
individuals: the “Checkerboard” appearance of the normal muscle
fibers is less distinct and certain fiber grouping can be observed
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FIGURE 1 | Muscle imaging at different ages and diseases. Normal muscle
imaging in a 40-year-old male (A). Normal muscle imaging in a 73-year-old
male with clear decrease in muscle volume (B). Slight increase of diffuse fatty
tissue is seen intramuscularly. Muscle CT in a 78-year-old male with LGMD2L
shows dystrophic changes in the hamstrings and gastrocnemius medialis
muscles (C). Muscle MRI findings in a patient with LGMD1D at age 73 with
typical fatty degenerative changes in the hamstring muscles and adductors at
thigh level in the soleus and gastrocnemius muscles in the calves (D). Muscle
MRI in a patient with DM2 (E) shows that muscle volume is normal, and fatty
degenerative changes are not seen at age 60.
in aging muscle tissue. The number of hybrid fibers, expressing
more than a single myosin heavy chain isoform, is also increased
(Doherty, 2003). Aging gradually increases the number of ragged
red fibers (RRF) and cytochrome c oxidase (COX)-negative
fibers (Müller-Höcker, 1992). There is no clear cut-point for
the amount of these changes between normal aging and mito-
chondrial myopathies. Thus, in cases where there are more than
occasional RRF or COX-negative fibers, late-onset mitochondrial
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or inflammatory myopathy (inclusion body myositis) should be
considered.
MUSCULAR DYSTROPHIES
Usually genetic myopathies manifest at birth, in childhood, or early
in adulthood, but many of them can also present at very old age
(Table 1). Typically, muscular dystrophies present with slowly pro-
gressive weakness and muscle atrophy. Especially, if the symptoms
are mild in severity and occur very late, the distinction between
normal age-related weakening of muscle strength and clinically
significant muscle disease is not always easy to make. Two entities
with disease manifestations beginning at an old age are discussed
in more detail.
LIMB-GIRDLE MUSCULAR DYSTROPHIES
Limb-girdle muscular dystrophies (LGMD) are a heterogeneous
group of muscle diseases affecting hip and shoulder region first.
There are eight autosomal dominant (LGMD1) and 23 autoso-
mal recessive (LGMD2) genes or loci identified to date (Nigro
and Savarese, 2014). Dominant diseases are usually adult-onset
and milder than recessive forms, and comprise around 10% of all
LGMD diseases. The age of onset of LGMD1 group of diseases
is typically before the age of 50 (Nigro and Savarese, 2014) but
occasional cases with later onset have been reported. LGMD1D
is caused by heterozygous missense mutations in DNAJB6 gene
(Sarparanta et al., 2012). The muscle symptoms start in the prox-
imal lower limbs at age 20–60 (Sandell et al., 2010). The weakness
progresses very slowly and most of the patients remain ambu-
lant even at very old age, although waddling gait is typical. In
recessive LGMD diseases, the severity of the symptoms varies sig-
nificantly. For example, LGMD2L disease caused by ANO5 gene
mutations can be very mild or even asymptomatic, especially in
female patients (Penttilä et al., 2012). Of the patients examined
in that study, one male patient’s symptoms started at age 70,
and at first, they were considered to be a consequence of statin
use. He had, however, proximal weakness in the lower limb on
examination and dystrophic changes on muscle MRI (Penttilä
et al., 2012). Another male patient with a very mild LGMD2L
disease is now 78 years old and still walking long distances without
aid. His muscle CT showed relatively severe dystrophic changes
(Figure 1C).
LGMD1D IN AN ELDERLY PATIENT
A 70-year-old sister, who at that time considered herself healthy,
accompanied her brother to the hospital who was known to carry
a DNAJB6 mutation and who had more severe weakness and
walking difficulties. She was found to carry the same mutation
confirming the diagnosis of LGMD1D. At the first examination,
she had mild weakness in the lower limbs, which progressed slowly
during the follow-up of 10 years. Muscle MRI showed, nonethe-
less, dystrophic changes in her muscles compatible with the earlier
findings of this disease (Figure 1D) (Sandell et al., 2013).
MYOTONIC DYSTROPHY TYPE 2
Myotonic dystrophies are the most common forms of muscular
dystrophies in adults, but exact epidemiological data for myotonic
dystrophy type 2 (DM2) are lacking. DM2 is, however, quite com-
mon at least in European populations. The mutation frequency is
1 in 1830 in the Finnish population, suggesting a clinical manifes-
tation frequency of 1 in 5000 (Suominen et al., 2011). Dominantly
inherited DM2 results from a (CCTG)n expansion in CNBP gene
(formerly ZNF9 gene) (Liquori et al., 2001). The phenotype of
Table 1 | Genetic muscle diseases that can present at a very old age.
Muscle disease Gene, locus Mutation type Age of onset
Tibial muscular dystrophy TTN (titin), 2q31 Dominant, insertion–deletion,
missense, truncating
35–40 distal weakness, rarely after
60 years; 60–80 proximal weakness
Welander distal myopathy TIA1, 2p13 Dominant, missense 40–60 infrequently after 60 years
LGMD1A TTID (myotilin), 5q31 Dominant, missense 50–60 up to 77 years
LGMD1D DNAJB6, 7q36.3 Dominant, missense 20–50 up to 70 years
IBMPFD VCP, 9p13.3 Dominant, missense Mean age 42 can be over 60
Oculopharyngeal muscular dystrophy PAPBN1, 14q11.2 Dominant/recessive, repeat expansion 50–60 or later in heterozygotes
DM1, late-onset oligosymptomatic DMPK, 19q13.3 Dominant, repeat expansion Over 50
DM2 CNBP (ZNF9), 3q21 Dominant, repeat expansion 20–60, proximal weakness
manifests later in typical cases




Early adulthood up to 72 years
Mitochondrial myopathy mtDNA defects Dominant/recessive, maternal,
sporadic, point mutations, deletions
Any age up to 70 years
LGMD, limb-girdle muscular dystrophies; IBMPFD, inclusion body myopathy with Paget disease and frontotemporal dementia; DM1, myotonic dystrophy type 1;
DM2, myotonic dystrophy type 2; mtDNA, mitochondrial DNA.
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DM2 is highly variable in severity, characterized by adult- or late-
onset proximal muscle weakness, myalgia, and myotonia. Beyond
the skeletal muscle symptoms, it is a multi-system disease and can
cause cardiac conduction deficits, cataracts, and hormonal prob-
lems, such as insulin resistance, mild cerebral involvement, and
liver enzyme elevation (Machuca-Tzili et al., 2005; Udd and Krahe,
2012).
DM2 IN ELDERLY PATIENTS
A 64-year-old female has had a slowly progressing myalgic syn-
drome for 15 years. The investigations begun when she experi-
enced recurrent rhabdomyolysis at age 56 while on statin med-
ication. Electromyogram showed spontaneous activity high fre-
quency discharges and increased insertional activity but no myoto-
nia. Between rhabdomyolysis periods, the levels of creatine kinase
(CK) were normal. Myalgia reduced her physical performance;
she was only able to walk 100 m at normal pace. Otherwise, the
muscle strength was normal and muscle MRI was within normal
limits (Figure 1E). Muscle biopsy showed minor changes sugges-
tive of DM2: a subpopulation of highly atrophic type 2 fibers,
nuclear clump fibers, and increased amount of internal nuclei.
DNA analysis revealed (CCTG)n expansion in CNBP gene con-
firming the diagnosis of DM2. The mutation was transmitted by
her mother, now at age 90. The mother was investigated after the
diagnosis was made in the daughter and proved to have had some
progressive walking difficulties and used a stick for walking since
age 80. She had regular visits at the primary health care because
of type 2 diabetes but her muscle weakness had not been noted
as abnormal for age. At examination, she had moderate proximal
lower limb weakness, even though she thought herself healthy for
the age.
DISCUSSION
Muscle weakness, gradually worsening walking difficulties, muscle
pain, and stiffness are common complaints in the elderly. Sar-
copenia begins in mid-late adulthood, but the age of onset and
the rate of muscle loss vary greatly between individuals. Normal
age-related processes lead to certain findings in muscle histology
and imaging studies. It is not always self-evident to consider the
possibility of a late-onset myopathy as a cause of muscle symptoms
in elderly people. However, old age should not limit investigations.
Comprehensive studies on myopathies in the elderly are scarce.
Laguno et al. (2002) studied muscle biopsies from 239 patients over
65 years and diagnosed specific myopathies in 36% of them. Most
of the causes of myopathies were other than genetic, i.e., inflam-
matory myopathies and vasculitis being the most frequent. They
identified dystrophies or congenital myopathies in 9% and meta-
bolic myopathies in 10% of the patients. Elderly patients showed
more non-specific type 2 fiber atrophy and fewer normal muscle
biopsies compared to younger patients (Laguno et al., 2002). This
was also shown in a similar study by Lacomis et al. (1993). These
studies proved that muscle biopsies are useful also in the elderly.
The findings can be subtle or non-specific as in our patient with
DM2, although together with the myalgic syndrome, they were
suggestive of DM2.
DM2 is a heterogeneous disease, and in the mild end of the
spectrum, not always obvious to suspect. This is particularly
true for patients without myotonia even on EMG and with nor-
mal CK levels, as was the case in the DM2 patient and in the
LGMD1D patient examples. Electromyogram is usually myo-
pathic in muscular dystrophies but can be normal and with-
out myotonia in DM2 (Udd and Krahe, 2012). Many DM2
patients experience myalgia, typically induced by exercise, as ini-
tial manifestation. The myalgic syndrome in DM2 cannot be
distinguished from fibromyalgia (Udd and Krahe, 2012). Prox-
imal muscle weakness manifests later, usually after 50–60 years
of age, even though, patients can remain asymptomatic until old
age. Rhabdomyolysis is not a known manifestation of DM2, and
without rhabdomyolysis, our patient could still be undiagnosed.
She has probably a second unknown cause for rhabdomyolysis.
Otherwise, the muscle disease was quite mild and even milder
in her mother showing the milder end of symptom severity
of DM2.
Muscle MRI (or CT) is useful and currently a widely used
tool to assess the distribution of affected muscles and to aid in
obtaining targeted muscle biopsy. Dystrophic changes, i.e., fatty
degenerative changes in muscle, are more reliably detected on MRI
compared to clinical evaluation. The pattern of affected muscles
can direct the diagnostic genetic investigations, which is explicit
in the case of LGMD1D (Sandell et al., 2013). When evaluating
a patient with a possibility of a neuromuscular disorder, a con-
comitant neurogenic disease is more prevalent in the elderly, such
as neuropathy or degeneration of the lumbar vertebrae causing
radiculopathy. Neurogenic and myogenic changes can, to some
extent, be distinguished by muscle imaging and sometimes unnec-
essary investigations or even a surgical operation can be avoided
by correct diagnosis.
The specific cause of the symptoms is the key to assess the right
therapeutic and rehabilitation measures, and to estimate prog-
nosis. A possibility of a genetic myopathy is important to bear
in mind also in the patients with very late-onset symptoms. If a
genetic muscle disease is diagnosed, it can have an impact for the
wider family and genetic counseling can be applied. Muscle MRI
is useful in the distinction and a recommended tool to help dif-
ferentiate myopathies from sarcopenia and to reach the correct
diagnosis also in the elderly.
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